PillRx only · Suspension · Oral
Naproxen
Naproxen
4 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US5 NDCs
4 active makers
4 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.143
Latest avg · Jul 22, 2026
-30%
Since Dec 17, 2025
4
Active US suppliers
50%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
5.5K
Rx · 2026 Q1
2.2M
Units dispensed
-13%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it4 active · 1 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | unknown | 1 | SUPPLYING |
| Aurobindo Pharma Limited | unknown | 1 | SUPPLYING |
| Camber Pharmaceuticals, Inc. | unknown | 1 | SUPPLYING |
| Amneal Pharmaceuticals LLC | unknown | 1 | SUPPLYING |
| Acella Pharmaceuticals, LLC | unknown | 1 | EXITED 2028 |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Apr 20, 2026RECALLRecall (Class II): NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, L…
Chemical contamination; presence of lead and lithium above specification — Recalling firm: Acella Pharmaceuticals, LLC — Nationwide